SBI Securities Co. Ltd. Invests $26,000 in NeoGenomics, Inc. (NASDAQ:NEO)

SBI Securities Co. Ltd. acquired a new position in NeoGenomics, Inc. (NASDAQ:NEO) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 1,553 shares of the medical research company’s stock, valued at approximately $26,000.

Several other large investors have also recently modified their holdings of NEO. Versant Capital Management Inc boosted its position in NeoGenomics by 174.9% during the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 1,142 shares in the last quarter. Quarry LP bought a new stake in shares of NeoGenomics in the 3rd quarter worth approximately $40,000. KBC Group NV boosted its position in shares of NeoGenomics by 33.1% in the 3rd quarter. KBC Group NV now owns 4,530 shares of the medical research company’s stock worth $67,000 after purchasing an additional 1,127 shares in the last quarter. Smartleaf Asset Management LLC lifted its position in NeoGenomics by 203.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 4,156 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 2,787 shares in the last quarter. Finally, Blue Trust Inc. lifted its position in NeoGenomics by 33.2% in the 4th quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company’s stock valued at $73,000 after acquiring an additional 1,103 shares in the last quarter. Hedge funds and other institutional investors own 98.50% of the company’s stock.

NeoGenomics Stock Down 6.9 %

NEO opened at $9.52 on Friday. NeoGenomics, Inc. has a twelve month low of $8.98 and a twelve month high of $19.12. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38. The company has a 50-day moving average price of $13.26 and a 200 day moving average price of $14.85. The company has a market cap of $1.22 billion, a PE ratio of -15.35 and a beta of 1.28.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Tuesday, February 18th. The medical research company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05). The business had revenue of $172.00 million during the quarter, compared to analyst estimates of $173.40 million. NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. Sell-side analysts expect that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

NEO has been the subject of several analyst reports. Piper Sandler reduced their price objective on NeoGenomics from $21.00 to $18.00 and set an “overweight” rating for the company in a research note on Wednesday, February 26th. Benchmark downgraded shares of NeoGenomics from a “buy” rating to a “hold” rating in a report on Monday, January 13th. The Goldman Sachs Group dropped their price objective on shares of NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Jefferies Financial Group initiated coverage on shares of NeoGenomics in a report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 price target for the company. Finally, Bank of America lowered their price target on shares of NeoGenomics from $19.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday, February 19th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $19.60.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.